X0202 SCHEDULE 13G/A 0000950103-22-001223 0001678057 XXXXXXXX LIVE 3 Ordinary shares, par value US$0.0001 per share 03/31/2026 0001818838 Adagene Inc. 005329107 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province F4 215123 Rule 13d-1(d) WuXi PharmaTech Healthcare Fund I L.P. b E9 0.00 3485038.00 0.00 3485038.00 3485038.00 5.9 HC WuXi AppTec Co., Ltd. b F4 0.00 3485038.00 0.00 3485038.00 3485038.00 5.9 HC Adagene Inc. 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, F4, 215123. The names of the persons filing this report (collectively, the "Reporting Persons") are: WuXi PharmaTech Healthcare Fund I L.P. ("PharmaTech") WuXi AppTec Co., Ltd. ("AppTec Co") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G. 288 Fute Zhong Road Pudong New Area Shanghai 200131, China PharmaTech Cayman Islands AppTec Co China Y CUSIP Number 005329107 has been assigned to the American Depositary Shares ("ADS") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "ADAG". Each ADS represents 1.25 ordinary shares of the Issuer. No CUSIP has been assigned to the Issuer's ordinary shares. Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of ordinary shares of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. PharmaTech directly holds 3,485,038 ordinary shares held in the form of 2,788,030 ADS. AppTec Co is the indirect parent company, and ultimate beneficial owner of, PharmaTech and shares voting and investment authority over these shares. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the ordinary shares of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 59,231,993 ordinary shares outstanding (including in the form of American Depositary Shares) as of December 31, 2025, as reported in the Issuer's Annual Report on Form 20-F filed with the Securities and Exchange Commission (the "SEC") on April 1, 2026. Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. Y Y Y Y Y Y Exhibit 99.1 Joint Filing Agreement by WuXi PharmaTech Healthcare Fund I L.P. and WuXi AppTec Co., Ltd., dated as of January 7, 2021 (incorporate by reference to Exhibit 99.1 from Schedule 13G filed by the Reporting Persons on January 8, 2021). WuXi PharmaTech Healthcare Fund I L.P. /s/ Ming Shi 05/15/2026 WuXi AppTec Co., Ltd. /s/ Ming Shi 05/15/2026